Streetbeat News

Equity Actions

IDYA

IDEAYA Biosciences (NASDAQ:IDYA) has received mixed analyst ratings over the last quarter, with 3 bullish and 5 somewhat bullish ratings. The average 12-month price target for IDYA is $44.5, with a high of $53.00 and a low of $36.00, representing a 16.49% increase from the previous average of $38.20. Analysts from firms including Goldman Sachs, RBC Capital, JP Morgan, Wedbush, and Guggenheim have updated their ratings and price targets. IDEAYA Biosciences is an oncology-focused precision medicine company with a negative revenue trend of -72.94% over 3 months and a high net margin of -341.38%. The company has a strong ROE of -5.44% and ROA of -5.17%, with no debt (debt-to-equity ratio of 0.0).

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 3:00 pm

URI

United Rentals (NYSE:URI) has received mixed analyst ratings over the last quarter, with 6 analysts offering varied opinions. The average 12-month price target for URI is $576.83, with a high estimate of $710.00 and a low of $485.00, marking an 8.94% increase from the previous target. Recent actions by analysts include rating changes and price target adjustments, reflecting their views on the company's performance and market conditions. United Rentals, the world's largest equipment rental company, has shown strong financials with a market cap above industry average, a revenue growth rate of 13.11%, a net margin of 18.21%, an ROE of 8.55%, an ROA of 2.64%, and a debt-to-equity ratio of 1.56.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 3:00 pm

ASB

Associated Banc (NYSE:ASB) has been analyzed by 4 analysts in the last three months, with all maintaining an indifferent rating. The average 12-month price target for ASB is $20.38, up from the previous $19.50. Analysts from RBC Capital, Keefe, Bruyette & Woods, and Piper Sandler have raised their price targets. Associated Banc operates in banking and nonbanking services, with the majority of revenue from Corporate and Commercial Specialty and Community, Consumer, and Business segments. The company's market cap is below industry averages, and it has seen a -4.44% decline in revenue growth, a net margin of 25.06%, an ROE of 2.03%, an ROA of 0.19%, and a high debt-to-equity ratio of 1.08.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 3:00 pm

PCSA

Processa Pharmaceuticals has announced the pricing of a $7 million public offering. This capital raise could impact the company's financial flexibility and potentially fund further development of its product pipeline.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:46 pm

BA

Moody's report indicates Boeing's 737 Max program is facing challenges, with one step forward and two steps back. The report suggests that while there has been progress, there are also setbacks that could affect the program's momentum and financial stability.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:29 pm

WINT

Windtree Therapeutics has removed a $15 million contingent liability owed to Deerfield Management Company, resulting in no significant debt on its balance sheet. This financial improvement positions Windtree favorably as it approaches later-stage clinical trials.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:22 pm

CAMP

CalAmp Corp. has announced a 1-for-23 reverse stock split, according to an SEC filing. This corporate action is typically used by companies to boost the share price by reducing the number of shares outstanding, which may help in meeting minimum bid price requirements and can also reduce volatility.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:09 pm

TKLF

Yoshitsu Co., Ltd. has announced the pricing of a registered direct offering of 5,970,152 American Depositary Shares (ADS) at $0.67 per ADS, raising a total of $4 million. Additionally, in a concurrent private placement, the company will sell investors warrants to purchase ADS at the same price of $0.67 per ADS.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:08 pm

PCSA

Processa Pharmaceuticals has announced a $10 million offering to raise capital. The specifics of the offering, such as pricing, number of shares, and use of proceeds, were not disclosed in the article.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 2:08 pm

VLY

Valley National Bancorp (NASDAQ:VLY), analyzed by 4 analysts, shows a consensus neutral stance with no bullish or bearish ratings. The average 12-month price target is $9.62, down from $10.67, with individual targets ranging from $8.00 to $11.00. Analysts from Wedbush, Citigroup, Piper Sandler, and JP Morgan have adjusted their price targets, reflecting a cautious outlook on the bank's performance. Valley Ntl's financials indicate a strong net margin and ROE, but revenue challenges and a market cap below industry benchmarks.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 2:01 pm